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FoxO transcription factors and TORC1 are con-
served downstream effectors of Akt. Here, we unrav-
eled regulatory circuits underlying the interplay
between Akt, FoxO, and mTOR. Activated FoxO1
inhibits mTORC1 by TSC2-dependent and TSC2-
independent mechanisms. First, FoxO1 induces
Sestrin3 (Sesn3) gene expression. Sesn3, in turn,
inhibits mTORC1 activity in Tsc2-proficient cells.
Second, FoxO1 elevates the expression of Rictor,
leading to increased mTORC2 activity that conse-
quently activates Akt. In Tsc2-deficient cells, the
elevation of Rictor by FoxO increases mTORC2
assembly and activity at the expense of mTORC1,
thereby activating Akt while inhibiting mTORC1.
FoxO may act as a rheostat that maintains homeo-
static balance between Akt and mTOR complexes’
activities. In response to physiological stresses,
FoxO maintains high Akt activity and low mTORC1
activity. Thus, under stress conditions, FoxO inhibits
the anabolic activity of mTORC1, a major consumer
of cellular energy, while activating Akt, which
increases cellular energy metabolism, thereby main-
taining cellular energy homeostasis.
INTRODUCTION
The serine/threonine kinase Akt delivers the effect of growth
factors and other extracellular signals on intracellular metabo-
lism in mammalian cells. The regulation of metabolism in general
and energy metabolism in particular both at the cellular and
organismal levels is the most evolutionarily conserved function
of Akt. The two most evolutionarily conserved downstream
effectors of Akt are the FoxO transcription factors and the target
of rapamycin complex 1 (TORC1), which comprises Raptor and
LST8. The mammalian FoxO transcription factors regulate cell
proliferation and life span through the transcriptional activation
of certain genes (Greer and Brunet, 2005), whereas the mamma-
lian TORC1 (mTORC1) regulates cell growth and proliferation
largely through the increase in protein synthesis. mTORC1
elevates mRNA translation by phosphorylating and activating
S6K1 and by phosphorylating and inhibiting the eIF4E-binding
protein (4E-BP), a repressor of mRNA translation (Mamane592 Developmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Iet al., 2006). Akt phosphorylates and inactivates the FoxO
transcription factors, whereas it indirectly activates TORC1.
mTORC1 and the Drosophila TORC1 are inhibited by the
TSC1/TSC2 heterodimer acting as a GAP for the small GTPase
Rheb, thereby inhibiting Rheb activity, which is required for
TORC1 activation. Akt activates TORC1 by phosphorylating
and inhibiting TSC2 activity (Inoki et al., 2002). The increase in
energy metabolism by Akt also contributes to the activation of
mTORC1. As a consequence of energy stress, AMPK is acti-
vated, and in turn inactivates mTORC1 by phosphorylating and
activating TSC2 (Inoki et al., 2003) and by phosphorylating
Raptor (Gwinn et al., 2008). The increase in intracellular energy
metabolism by Akt inhibits AMPK, thereby contributing to
mTORC1 activation (Hahn-Windgassen et al., 2005).
Cells have evolved a feedback mechanism to maintain an
optimal balance between the activities of Akt and mTORC1;
thus, after mTORC1 is activated by Akt, it institutes a negative-
feedback loop to inhibit Akt (Harrington et al., 2004). The inter-
play between Akt and mTOR is further complicated because
mTOR is the catalytic component of another protein complex,
mTORC2, which includes, in addition to mTOR, Rictor, Sin1,
and mLST8. mTORC2 phosphorylates Akt at Ser473 in the
hydrophobic motif and activates Akt (Sarbassov et al., 2005).
In Caenorhabditis elegans and Drosophila, interplays between
TORC1 and FoxO have been reported. In C. elegans, the FoxO
ortholog, DAF-16, was shown to inhibit TORC1 activity by inhib-
iting the expression of Raptor (Jia et al., 2004), which is required
for the activity of TORC1. In Drosophila, FoxO was shown to
elevate the expression of 4E-BP, thereby negating the effect of
TORC1 on mRNA translation (Puig et al., 2003). However, it is
not known if such interplay operates in mammalian cells.RESULTS
Activated FoxO1 Inhibits mTORC1 and Activates Akt
To determine whether there is interplay between FoxO and
mTORC1 in mammalian cells, we introduced an inducible Fox-
O1(AAA) mutant, in which the three Akt phosphorylation sites
were mutated to alanines, fused in frame with the estrogen
receptor (ER) ligand-binding domain (FoxO1(AAA)-ER). The
activity of FoxO1(AAA) is elevated upon addition of 4-hydroxy
tamoxifen (4-OHT), which binds the ligand-binding domain
and triggers a conformational change to activate the latent
FoxO1(AAA)-ER.
Rat1a cells or Rat1a cells expressing constitutively active myr-
istoylated Akt (Rat1a-mAkt) were infected with FoxO1(AAA)-ERnc.
Figure 1. Activation of FoxO1 Downregulates
mTORC1, but Elevates Akt, Activity
(A) Activated FoxO1 represses mTORC1 activity. Rat1a
cells stably expressing FoxO1(AAA)-ER were treated
with 300 nM 4-hydroxy tamoxifen (4-OHT) to induce
FoxO1(AAA) activity. Total proteins were extracted,
adjusted for similar amounts of total S6K1, and subjected
to immunoblotting with the indicated antibodies.
(B and C) FoxO1 downregulates mTORC1 activity but
elevates Akt activity. NIH 3T3, DOV13, MCF7, and U2OS
cells were infected with either FoxO1(AAA) adenovirus or
control virus. A total of 48 hr after adenovirus infection,
total protein was extracted and subjected to immunoblot-
ting with the indicated antibodies.
(D) Tsc2+/ and Tsc2/ MEFs stably expressing
FoxO1(AAA)-ER were treated with 4-OHT to activate
FoxO1. A total of 16 hr after this treatment, total proteins
were extracted and subjected to immunoblotting.
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Figure S1A available online). Upon addition of 4-OHT to activate
FoxO1(AAA)-ER, a reduction in mTORC1 activity was observed
in Rat1a cells, as measured by S6K1 phosphorylation and
a 4E-BP1 mobility shift (Figure 1A; Figure S1A). The induction
of FoxO activity was confirmed by the increase in the p27 protein
level (Figure S1A), a known downstream target of FoxO (Greer
and Brunet, 2005). Interestingly, the reduction in mTORC1
activity, as assessed by S6K1 phosphorylation, occurred even
in Rat1a (mAkt) cells that display higher S6K1 phosphorylation
(Figure S1A), suggesting that activated FoxO is able to reduce
mTORC1 activity even when Akt is hyperactivated. To further
confirm these results, cells were infected with adenovirus ex-
pressing FoxO1(AAA). After infection of NIH 3T3 with adenovirus
expressing FoxO1(AAA), we observed, like in Rat1a cells,
a reduced p-S6K1 as well as S6 phosphorylation (Figure 1B).
The results were also substantiated in human cells. After infec-
tion of the human cell lines DOV13, MCF7, and U2OS with
adenovirus expressing FoxO1(AAA), we found that, as is
observed with rodent cells, mTORC1 activity, as assessed by
S6K1 phosphorylation, was reduced (Figure 1C). Notably, we
also observed Akt activation, as assessed by Ser473 phosphor-
ylation of Akt (Figures 1B and 1C; see below). Overall, these
results show that mTORC1 activity is decreased when cells
possess high FoxO activity.
mTORC1 activity is tightly regulated by multiple distinct
signaling inputs such as growth factor stimulation, amino acid
withdrawal, energy homeostasis, and hypoxia (reviewed in
Bhaskar and Hay, 2007). Among all of the upstream regulators,
tuberous sclerosis complex (TSC) is considered to be the most
important regulator, as it converges multiple upstream inputs
to regulate mTORC1 activity. To further clarify the mechanism
by which FoxO regulates mTORC1 activity, we stably expressed
FoxO1(AAA)-ER in Tsc2+/ and Tsc2/ MEFs (Figure 1D). As
expected, activation of FoxO1 led to a reduced mTORC1 activity
in Tsc2-proficient cells (Figure 1D). Surprisingly, however, weDevelopmental Cell 18found that the activation of FoxO1 reduced
mTORC1 activity even in Tsc2-deficient cells
(Figure 1D). Once again, we observed a marked
increase in Akt phosphorylation at Ser473, bothin Tsc2-proficient and Tsc2-deficient cells. Notably, activation of
FoxO(AAA)-ER after the addition of 4-OHT could elevate Akt
activity and reduce mTORC1 activity even when cells were
cultured in medium with 0.1% serum (Figure S1B). In the
absence of FoxO(AAA)-ER, 4-OHT could not affect either
mTORC1 or Akt activities (Figure S1C).
Taken together, these results suggest that activated FoxO1
reduces mTORC1 activity while increasing Akt activity, thereby
uncoupling Akt and mTORC1 activities. Interestingly, after
long-term FoxO activation, the protein level of S6K1 was also
reduced (Figures 1B and 1D; Figure S1A) even though the
mRNA levels of S6K1 remain constant (data not shown), sug-
gesting that FoxO can also regulate S6K1 activity downstream
of mTORC1 by reducing the S6K1 protein level.
FoxO1 Inhibits mTORC1 Activity by Elevating
Sesn3 Expression
Recent studies showed that p53 downregulates mTORC1
activity by elevating the expression of Sestrin1 (Sesn1) and
Sestrin2 (Sesn2), which, in turn, activate TSC2 by activating
AMPK (Budanov and Karin, 2008). The Sestrin gene family
comprises three members, Sesn1, Sesn2, and Sesn3. Because
we had previously shown that FoxO exclusively elevates the
expression of Sesn3 (Nogueira et al., 2008), we examined
whether FoxO downregulates mTORC1 activity via the upregu-
lation of Sesn3. We first substantiated our previous results and
showed that activation of FoxO1 specifically elevates the
expression of Sesn3, but not Sesn1 or Sesn2 (Figure 2A). In
Tsc2+/ cells, the Sesn3 mRNA level is elevated by up to
7-fold after 24 hr of FoxO1 activation. However, Sesn1 and
Sesn2 show no obvious induction at the same time point.
Similar results were obtained in MCF7 and U2OS cells infected
with adenovirus carrying FoxO1(AAA). FoxO1(AAA) elevates the
Sesn3 mRNA level by up to 5-fold in MCF7 cells, whereas
FoxO1(AAA) activated Sesn1 very modestly and did not affect
Sesn2 in MCF7 cells., 592–604, April 20, 2010 ª2010 Elsevier Inc. 593
Figure 2. FoxO1 Binds the Promoter Region of the Sestrin3 Gene and Directly Induces Its mRNA Levels
(A) FoxO1 increases the Sesn3 mRNA level. Total RNA was isolated from Tsc2+/ MEFs stably expressing FoxO1(AAA)-ER in the absence or presence of 4-OHT
or from FoxO1(AAA) adenovirus- or control adenovirus-infected MCF7 and U2OS cells. mRNA levels were quantified by quantitative real-time PCR as described
in Experimental Procedures. Fold change in mRNA levels was calculated by normalizing to actin mRNA.
(B) DNA-binding-deficient FoxO1 cannot induce Sesn3 mRNA. Total RNAs were extracted from Tsc2+/ cells stably expressing FoxO1(AAA)-ER or FoxO1H215-
R(AAA)-ER in the absence or presence of 4-OHT. Relative mRNA levels were determined by quantitative real-time PCR. The insert shows the levels of FoxO1AAA
and FoxO1H215R(AAA).
(C) The induction of Sesn3 mRNA by FoxO1 does not require de novo protein synthesis. Tsc2+/ FoxO1(AAA)-ER cells were treated with cycloheximide (CHX)
for 1 hr prior to the addition of 4-OHT to prevent de novo protein synthesis. After the addition of 4-OHT for 4 hr, relative levels of mRNA were determined by
quantitative real-time PCR.
(D) FoxO1 directly binds to the promoter region of the Sesn3 gene. U2OS cells were infected with FoxO1(AAA) adenovirus and then subjected to a ChIP assay
with FoxO1 antibodies, as described in Experimental Procedures. The localization of the binding region within the first intron of the Sesn3 gene is indicated
schematically. Sequences show four predicted consensus FoxO-binding sites highlighted within the binding region. The high homology of these sequences
between the mouse and human Sesn3 genes is shown.
(E) FoxO1 regulates transcription from the Sesn3 promoter in a luciferase reporter assay. FoxO1(AAA) MEFs were transfected with a pGL3-Sesn3 promoter or
a conventional pGL3-IRS3 (three copies of insulin response element of IGFBP1 promoter) construct as a positive control. Cells were treated with or without 4-OHT
and subjected to a Dual-Luciferase reporter assay (Promega). Luciferase activities were normalized to a coexpressed Renilla luminescent signal and are shown
as relative folds against control samples.
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expression of Sesn3 mRNA, we first determined whether the
elevation of Sesn3 by FoxO1 is dependent on its DNA binding,
and if Sesn3 is a direct target gene of FoxO. To verify whether
the DNA-binding activity of FoxO1 is required for the induction
of Sesn3 mRNA, we used a mutant of activated FoxO1 in which
His215 was mutated to arginine that is impaired in DNA binding594 Developmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier I(Tang et al., 1999). The mutant H215R on the background
of FoxO1 mutated in the three Akt phosphorylation sites was
fused in frame to the ER ligand-binding domain to generate
FoxO1H215R(AAA)-ER-expressing retrovirus. The retrovirus
was then used to generate a polyclonal cell line stably express-
ing the H215R mutant. As shown in Figure 2B, upon addition of
4-OHT, the H215R mutant was unable to elevate Sesn3 mRNAnc.
Figure 3. FoxO1 Inhibits mTORC1 Activity by Elevating Sesn3 Expression
(A) Overexpression of Sesn3 downregulates mTORC1 activity. HEK293 cells were transiently transfected with Sesn3L, Sesn3S, or control plasmid. A total of 48 hr
after transfection, total proteins were extracted and subjected to immunobloting with the specified antibodies.
(B) Sesn3 represses mTORC1 activity in a TSC2-dependent manner. Tsc2+/ and Tsc2/ cells were transiently cotransfected with Sesn3 and myc-S6K1 plas-
mids. A total of 24 hr after transfection, total protein extracts were subjected to immunoprecipitation with 9E-10 myc-tag antibody, followed by immunobloting
with anti-p-S6K1, 9B-11 myc-tag, and anti-Sesn3 antibodies.
(C and D) The knockdown of Sesn3 attenuates the inhibition of mTORC1 activity by FoxO. Tsc2+/ FoxO1(AAA)-ER cells were transfected with Sesn3 or control
RNAi. A total of 48 hr after transfection, cells were treated with 4-OHT and harvested at the indicated time points for (C) protein and (D) RNA analyses. mTORC1
activity was deduced from three independent experiments and was quantified by the ratio of pS6K1 to S6K1. Data are presented as the mean ± standard error of
the mean.
(E) The knockdown of Sesn3 has no effect in Tsc2/ cells. Tsc2/ FoxO1(AAA)-ER cells were transfected with Sesn3 or control RNAi. A total of 48 hr after
transfection, cells were treated with 4-OHT and harvested at the indicated time points for protein and RNA analyses.
(F) Activated FoxO1 elevates AMPK activity as measured by pACC. MCF7 cells were infected with either FoxO1(AAA) (A3) adenovirus or control virus (E) for 24 hr.
Cell lysates were subjected to immunobloting with the indicated antibodies.
(G) The knockdown of AMPKa hindered FoxO1-mediated inhibition of mTORC1 activity without an effect on the increased Akt activity by FoxO1. MCF7 cells
stably expressing AMPKa or control shRNA were infected with either FoxO1(AAA) (A3) adenovirus or control virus (E) for 24 hr. Whole-cell lysates were subjected
to immunoblotting with the indicated antibodies.
Developmental Cell
Uncoupling of Akt and mTORC1 Activities by FoxOlevels, suggesting that the elevation of Sesn3 mRNA levels by
FoxO1 requires the DNA-binding activity of FoxO1. To determine
whether FoxO1 directly induces Sesn3 mRNA, we treated
the cells with cycloheximide (CHX) prior to the induction of
FoxO1(AAA)-ER activity by using 4-OHT to prevent de novo
protein synthesis. As shown in Figure 2C, CHX alone did not
affect the level of Sesn3 mRNA and did not inhibit the ability of
FoxO1(AAA)-ER to induce Sesn3 mRNA, indicating that de
novo protein synthesis is not required. These results imply that
FoxO1 directly induces Sesn3 transcription. Indeed, we found,
by using chromatin immunoprecipitation (ChIP), that FoxO1
binds to a 250 bp region within the first intron of Sesn3
(Figure 2D). This region possesses multiple predicted FoxO-
binding sites that are conserved in the human and the mouseDevegenes (Figure 2D). Cloning this region in a luciferase reporter
plasmid shows that it can activate transcription mediated by
FoxO1 (Figure 2D). The results indicate that FoxO1 binds directly
to the promoter region of the Sesn3 gene and transcriptionally
upregulates Sesn3 mRNA expression.
We next determined whether Sesn3 could regulate mTORC1
activity. The human Sesn3 gene gives rise to two alternatively
spliced variants that encode for two proteins, a 53 kDa form
(Sesn3L) and a 44 kDa short form (Sesn3S), which is missing
the N-terminal 79 amino acids. Overexpression of Sesn3L in-
hibited the phosphorylation of S6K1 in HEK293 cells. Sesn3S
overexpression also inhibited S6K1 phosphorylation, but to
a less extent (Figure 3A). We next overexpressed Sesn3 in
Tsc2+/ and Tsc2/ MEFs (Figure 3B), and we found thatlopmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Inc. 595
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Tsc2/, cells. Thus, like what had been shown for Sesn1 and
Sesn2 (Budanov and Karin, 2008), Sesn3 also downregulates
mTORC1 activity through TSC2.
To verify if the elevation of Sesn3 by FoxO determines, at least
in part, the ability of FoxO to attenuate mTORC1 activity, we
knocked down Sesn3, when FoxO was activated, and examined
mTORC1 activity. Sesn3 RNA interference (RNAi) or control
RNAi were transiently transfected into Tsc2+/ MEFs with
FoxO1(AAA)-ER. Using Sesn3 RNAi, we reduced 85% of
Sesn3 mRNA as quantified by quantitative real-time polymerase
chain reaction (real-time PCR) at the 0 hr time point (Figure 3D).
However, because FoxO forcefully elevates Sesn3 mRNA, the
knockdown of Sesn3 was less effective at later time points.
Nevertheless, p-S6K1 was monitored for up to 12 hr, and the
results revealed that the ability of FoxO1 to repress mTORC1
activity in the absence of Sesn3 is impaired (Figure 3C). In
Tsc2/ cells, however, the knockdown of Sesn3 did not affect
the reduced phosphorylation of S6K1 by activated FoxO1
(Figure 3E). We therefore concluded that the elevation of
Sesn3 is one potential mechanism by which FoxO regulates
mTORC1 activity in Tsc2-proficient cells.
The mechanism by which Sesn1 and Sesn2 inhibit mTORC1
was shown to be via the activation of AMPK preferentially toward
TSC2 (Budanov and Karin, 2008). Consistently, activated FoxO1
elevated AMPK activity as measured by p-ACC (Figure 3F), and
the knockdown of AMPKa in MCF7 cells inhibited the effect of
FoxO on mTORC1 activity (Figure 3G). Notably, Akt activity
was elevated even though mTORC1 activity was not significantly
reduced, suggesting that the increase in Akt activity is not only
due to the inhibition of the negative-feedback loop normally
operating through mTORC1 and S6K1 activation (see below).
We also found that Sesn3 elevates AMPK activity, and the
knockdown of AMPK or the inhibition of AMPK activity attenu-
ated the effect of Sesn3 on mTORC1 activity (Figure S2).
FoxO Transcription Factors Upregulate mTORC1
Activity by the Elevation of Rictor
The results presented above clearly show that FoxO downregu-
lates mTORC1 activity via the elevation of Sesn3 in a TSC2-
dependent manner. However, as shown in Figures 1D, 3E, and
3G, activation of FoxO could also downregulate mTORC1
activity and could elevate Akt phosphorylation in Tsc2-deficient
cells, independently of Sesn3, suggesting an additional TSC2-
independent mechanism by which FoxO inhibits mTORC1, while
elevating Akt activity.
To understand the mechanism by which FoxO exerts its effect
independently of TSC2, we first examined the expression of
mTORC1 and mTORC2 components by quantitative real-time
PCR after FoxO1 activation. The elevation of p27 and the reduc-
tion of cyclin D1 mRNA levels served as a control for FoxO1(AAA)
activity. As shown in Figure 4A, none of the mRNAs encoding the
various proteins comprising mTORC1 and mTORC2 were signif-
icantly affected by FoxO1 activation, except Rictor. Analysis of
protein levels also did not show any significant change, except
for Rictor (Figure 4B). Similar results were observed in Rat1a
cells (Figures 4C and 4D) and in Tsc2+/ MEFs (Figure S3A).
The increase in Rictor mRNA and protein levels by FoxO1 was
also observed in MCF7 and U2OS cells (Figure S3B). This596 Developmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Iincrease is associated with an increase in mTORC2 levels
(Figure S3C).
Rictor is upregulated by activated FoxO1 at the mRNA level.
At 8 hr after FoxO1 activation, we detected an 3- to 4-fold
induction of Rictor mRNA, which is comparable to or higher
than the elevation of p27 mRNA (Figures 4A and 4C). Thus,
FoxO1 elevates Rictor mRNA and protein levels in mammalian
cells. However, unlike the induction of Sesn3 mRNA by FoxO,
the elevation of Rictor mRNA appears to be independent of
DNA binding because the H215R mutant was still able to elevate
Rictor mRNA, repress mTORC1 activity, and elevate Akt activity
in Tsc2/ cells (Figures S3D and S3E). Therefore, unlike the
induction of Sesn3, the DNA-binding activity of FoxO1 is not
required to elevate Rictor mRNA, suggesting that FoxO1
elevates Rictor mRNA through the association with another
transcription factor that possesses DNA-binding activity. The
onset of the increase in the Rictor protein level was observed
4 hr after FoxO1 activation in Tsc2/ cells and remains high
at the 24 hr time point (Figures 4B and 4D). The elevation of
the Rictor protein level parallels the induction in the Rictor
mRNA level (Figure S3F). Interestingly, in Tsc2/ cells, the
timing of Rictor activation coincides with the change of both
mTORC1 activity and Akt activity, as measured by Ser473 and
Thr308 phosphorylation (Figure 4B). This is consistent with our
observation that overexpression of Rictor could elevate Thr308
phosphorylation in addition to Ser473 phosphorylation (Fig-
ure S4A). This is in accord with previous results suggesting
that Ser473 phosphorylation could enhance or sustain Thr308
phosphorylation (Yang et al., 2002). This is in contrast to what
was observed with cells deleted for Rictor from birth, in which
the phosphorylation of Thr308 is elevated, possibly as a compen-
sation mechanism (Guertin et al., 2006). However, acute knock-
down of Rictor was shown to affect both Thr308 and Ser473
phosphorylation (Hresko and Mueckler, 2005; Sarbassov et al.,
2005), which is consistent with results showing that pharmaco-
logical inhibitors of mTORC2 also inhibit Thr308 phosphorylation
(Feldman et al., 2009). Collectively, the results suggest that
Rictor could be a potential candidate that determines FoxO-
mediated regulation of both Akt activity and mTORC1 activity,
particularly in Tsc2-deficient cells. Indeed, it was previously
shown that the knockdown of Rictor not only reduces Akt
activity, but also elevates mTORC1 activity as measured by
S6K1 phosphorylation (Sarbassov et al., 2004, 2005). One
potential mechanism by which Rictor could affect both mTORC1
and Akt activities is by competing with Raptor on the assembly of
mTORC1 versus mTORC2. By increasing the assembly of
mTORC2, at the expense of mTORC1, the elevation of Rictor
could inhibit mTORC1 activity. Consequently, Akt activity would
be elevated by both increasing mTORC2 activity and by
decreasing mTORC1 activity that otherwise inhibits Akt activity
via the negative-feedback loop. However, as shown in Figure 3G,
Akt activity was elevated by FoxO even when S6K1 activity was
not reduced, suggesting that FoxO can elevate Akt activity
independently of the negative-feedback loop. Furthermore, Akt
activity was elevated in Tsc2/ cells by the H215R mutant of
FoxO1 (Figure S3E) that could not activate Sesn3 (Figure 2B).
To demonstrate that FoxO1 could elevate Akt activity through
the elevation of Rictor even if the negative-feedback loop is in-
hibited, we treated the cells with rapamycin in the absence ornc.
Figure 4. FoxO1 Upregulates Rictor mRNA and Protein Levels, which Coincides with mTORC1 Inhibition and Akt Activation in Tsc2/ Cells
(A and B) FoxO1 elevates Rictor mRNA and protein levels, but not other components of mTOR complexes in Tsc2/ MEFs. Tsc2/ FoxO1(AAA)-ER cells were
untreated or treated with 4-OHT and were harvested at the indicated time points for RNA and protein analyses. Total RNA was analyzed by quantitative real-time
PCR as described in Experimental Procedures. Total protein was subjected to immunoblotting with the specified antibodies.
(C and D) FoxO1 elevates Rictor mRNA and protein levels, but not other components of mTOR complexes in Rat1a cells. Experiments were performed as
described in (A) for Tsc2/ MEFs.
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rapamycin and FoxO1 activation elevated Akt activity above
levels observed with rapamycin alone (Figure S4B).
To directly verify the possibility that changing Rictor levels
could affect both mTORC2 and mTORC1 activities, we first
knocked down Rictor by using lentivirus expressing Rictor short
hairpin RNA (shRNA) in Tsc2/ cells, which also express
FoxO1(AAA)-ER. A total of 72 hr post-lentivirus infection, we
detected 60% reduction in the Rictor protein level with a
concomitant increase in S6K1 phosphorylation as compared
with cells infected with control virus (Figure 5A). To determine
if overexpression of Rictor could reduce mTORC1 activity, we
transiently overexpressed FoxO or Rictor in HEK293 cells
together with S6K1, and we observed a marked decrease in
S6K1 phosphorylation as compared with control cells (Figure 5B,
lanes 1 and 3). The reduction of mTORC1 activity by Rictor
overexpression was similar to that observed after FoxO1(AAA)Deveoverexpression in HEK293 cells (Figure 5B, lanes 1 and 2).
Moreover, overexpression of Rictor in HEK293 cells increased
Rictor’s association with mTOR, but it decreased the association
of Raptor with mTOR (Figure 5C). Taken together, these results
provide evidence that altering Rictor levels, the defining compo-
nent of mTORC2, is able to affect mTORC1 activity.
To directly assess the effect of FoxO-induced Rictor on the
elevation of Akt activity and on the inhibition of mTORC1 activity
in Tsc2/ cells, we determined whether the knockdown of
Rictor could impair the ability of FoxO to attenuate mTORC1
activity and to elevate Akt activity. For this purpose, we knocked
down Rictor to a level that does not markedly affect basal S6K1
phosphorylation (Figure 5D, lanes 1 and 5). We followed the
kinetics of Rictor elevation, S6K1 phosphorylation, and Akt
phosphorylation in Tsc2/ cells after activation of FoxO1 and
the knockdown of Rictor. In cells expressing control shRNA,
we observed a reduction of p-S6K1 after FoxO activationlopmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Inc. 597
Figure 5. Rictor Regulates mTORC1 and
mTORC2 Activities Downstream of FoxO
(A) The knockdown of Rictor elevates mTORC1
activity. Tsc2/MEFs were infected with lentivirus
expressing shRNA targeting Rictor. A total of 72 hr
after infection, cells were harvested for immuno-
blotting with the indicated antibodies.
(B) Overexpressing of Rictor represses mTORC1
activity to a similar extent as activated FoxO1.
HEK293 cells were transiently transfected with
FoxO1(AAA), Rictor, or control vectors. A total of
24 hr after transfection, total protein was extracted
and subjected to immunoblotting.
(C) Overexpression of Rictor increases the Rictor-
mTOR interaction and decreases the Raptor-
mTOR interaction. HEK293 cells were transiently
transfected with HA-Rictor or control DNA. A total
of 48 hr after transfection, total protein was har-
vested and subjected to coimmunoprecipitation
with mTOR antibody and immunoblotting with
specific antibodies.
(D) The knockdown of Rictor in Tsc2/ MEFs
impairs the ability of FoxO1 to regulate mTORC1
and Akt activities. Tsc2/ FoxO1(AAA)-ER cells
were infected with lentivirus expressing shRNA
targeting Rictor. A total of 48 hr after infection, cells
were treated with 4-OHT. At the indicated time
points, cell lysates were prepared and subjected
to immunobloting with the indicated antibodies.
A representative immunoblot is shown. The right
panels show the quantification of mTORC1 and
Akt activities after FoxO1 activation in the absence
or presence of Rictor shRNA. Relative mTORC1
activity, as quantified by the ratio of pS6K1 to
S6K1, and relative Akt activity, quantified by the
ratio of pAkt to Akt, were assessed in three inde-
pendent experiments. Data are presented as the
mean ± standard error of the mean.
(E) Activated FoxO1 decreases the Raptor-mTOR
interaction, increases the Rictor-mTOR interaction,
and inhibits mTORC1 kinase activity in vitro.
Tsc2/ FoxO1(AAA)-ER cells were treated with or
without 4-OHT and harvested for coimmunopreci-
pitation. Samples were immunoprecipitated by
mTOR antibody and subjected to immunoblotting
and in vitro kinase assays (bottom panels). In vitro
kinase assays for mTORC1 activity were performed
with unphosphorylated S6K1 and recombinant 4E-
BP1 (see Experimental Procedures).
(F) Activated FoxO1 increases mTORC2 kinase activity in vitro. Tsc2/ FoxO1(AAA)-ER cells were treated with or without 4-OHT and harvested for coimmu-
noprecipitation. Samples were immunoprecipitated by Rictor antibody and subjected to immunoblotting and in vitro kinase assays (bottom panel). An in vitro
kinase assay for mTORC2 activity was performed with unphosphorylated Akt1 (see Experimental Procedures).
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than 60% at 8 hr after the addition of 4-OHT (Figure 5D).
However, cells expressing Rictor shRNA displayed a significantly
slower rate of decline of pS6K1, with only an 15% decline at
8 hr after the addition of 4-OHT (Figure 5D). The reduced
ability of Rictor knockdown to overcome the effect of FoxO on
S6K1 phosphorylation, at later time points, is probably due to
the continuous elevation of Rictor mRNA by FoxO (Figure 5D,
lane 8). Thus, knocking down Rictor hinders the ability of FoxO
to downregulate mTORC1 activity. The results suggest that
Rictor elevation is required for the effect of FoxO on mTORC1
in Tsc2-deficient cells.598 Developmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier IRictor is the primary determinant of mTORC2 activity as a
kinase that phosphorylates Akt at Ser473 (Sarbassov et al.,
2005). To evaluate whether Rictor plays a role in FoxO-mediated
Akt activation, we also followed Akt phosphorylation after Rictor
knockdown. As shown in Figure 5D, after the activation of
FoxO1, for 6 hr, Ser473 phosphorylation of Akt was elevated
6-fold. However, the knockdown of Rictor significantly attenu-
ated the increase in Akt phosphorylation, indicating that Rictor
elevation is required for the effect of FoxO on Akt activity.
To determine if activated FoxO1 could increase the assem-
bly of mTORC2, while decreasing the assembly of mTORC1,
we performed a coimmunoprecipitation to pull down bothnc.
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observed, as expected, an elevated Rictor protein level in total
cell extract (Figure 5E). The same cell lysates were incubated
with mTOR antibody to pull down both mTORC1 and mTORC2
complexes. The immunoprecipitates were subjected to immuno-
blotting with Rictor antibody and showed increasing amounts of
Rictor-bound mTOR after FoxO1(AAA) activation, suggesting an
increase in mTORC2 formation (Figure 5E). At the same time, we
observed a reduction of Raptor-bound mTOR, suggesting a
decrease in mTORC1 assembly. Thus, our data suggest that,
by elevating the expression of Rictor, FoxO increases mTORC2
activity at the expense of mTORC1, thereby elevating Akt activity
and reducing mTORC1 activity. To further corroborate the
results, the immunoprecipitates were subjected to mTORC1
kinase assays. We first used S6K1 as a substrate and found
that the phosphorylation of S6K1 was reduced to a similar extent
as observed in vivo (Figure 5E). Interestingly, using recombinant
4E-BP1 as a substrate, we found that after 10 min of incubation
the phosphorylation of Thr37/46 was only modestly reduced
(data not shown). After 20 min of incubation, there was no differ-
ence in the in vitro phosphorylation of Thr37/46 before and after
FoxO1 activation. However, we reproducibly observed a
dramatic reduction in the in vitro phosphorylation of Ser65 after
FoxO1 activation (Figure 5E). This reduction in the in vitro phos-
phorylation of Ser65 is much more pronounced than the reduc-
tion in the amount of Raptor associated with mTOR. Although
we do not understand this discrepancy, one possibility is that
FoxO only affects the rapamycin-sensitive activity of mTORC1,
because Thr37/46 phosphorylation is not affected by rapamycin,
whereas Ser65 phosphorylation is rapamycin sensitive (Feldman
et al., 2009) (also see Discussion).
To determine that indeed FoxO activation leads to an increase
in mTORC2 activity, we conducted an in vitro mTORC2 kinase
assay by using Akt as a substrate. Because the level of mTORC2
is very low in TSC2/ cells, and because the conditions for
the extraction and immunoprecipitation of mTORC1 are not
optimized for the mTORC2 kinase assay, we could not perform
the mTORC2 kinase assay with the mTOR immunoprecipitates
used in Figure 5E. Therefore, immunoprecipitation with anti-
Rictor antibodies was performed before and after induction
of FoxO1 (Figure 5F). Clearly, mTORC2 kinase activity was
increased to a similar extent as the observed increase in Akt
phosphorylation by immunobloting (Figure 5F). Collectively,
these results support the notion that, by elevating the expression
of Rictor, FoxO could inhibit mTORC1 activity while increasing
mTORC2 and Akt activities.
FoxO Deficiency Activates mTORC1 Activity While
Reducing Akt Activity
The results shown above employed gain-of-function ap-
proaches to determine the FoxO regulation of mTORC1 and Akt
activities. We therefore employed a loss-of-function approach to
further substantiate our results. As we have shown previously,
Sesn3 levels are reduced in FoxO3a/ MEFs, as FoxO3a is
the major FoxO isoform expressed in MEFs (Nogueira et al.,
2008). However, in standard culture conditions of 10% FBS
and 25 mM glucose, we observed only a modest increase of
p-S6K1 and a modest decrease of p-Akt in FoxO3a-deficient
MEFs, and only after serum stimulation, as compared to FoxO3aDevewild-type MEFs (data not shown). We therefore knocked down
FoxO1 in FoxO3a/ MEFs (Figure 6A; Figure S5A). By tran-
siently transfecting FoxO1 RNAi into FoxO3a/ MEFs, we
reduced 80% of FoxO1 mRNA and protein levels (Figure 6A).
In response to the knockdown of FoxO1, we observed an
elevated S6K1 phosphorylation, indicating an increase in
mTORC1 activity, and a decrease in Akt phosphorylation, indi-
cating an increase in mTORC1 activity (Figure 6A). When
FoxO3a/ cells were cultured in 5 mM glucose, we observed
a marked increase in S6K1 phosphorylation and a decrease in
Akt phosphorylation as compared with WT cells (Figure 6B).
These results suggest that, in the presence of a high serum
concentration (10% FBS) and a high glucose level (25 mM), the
Sesn3 level should be reduced below a certain threshold in order
to have a significant effect on mTORC1 activity. We also
knocked down FoxO1 and FoxO3a in Tsc2/ MEFs (Fig-
ure S5B). Although Tsc2/ cells maintain high endogenous
mTORC1 activity, knocking down FoxO1 or both FoxO1 and
FoxO3a reduced Rictor levels and elevated S6K1 phosphoryla-
tion as compared with control RNAi-transfected cells (Figure 6C;
Figure S5C). The reduction in the Rictor level after the knock-
down of FoxO1 in Tsc2/ cells is also associated with a
decrease in Akt phosphorylation and in the amounts of Rictor
interacting with mTOR (Figure 6C). Notably, the decrease in
the Rictor level by the knockdown of FoxO1 was not further
decreased by the additional knockdown of FoxO3a (Figure S5C),
reinforcing the possibility that Rictor expression is preferentially
regulated by FoxO1. Taken together, these results further con-
firmed that FoxO1 regulates Rictor expression in mammalian
cells. We propose that under growth factor limitations or other
physiological stress conditions when FoxO transcription factors
are activated, they inhibit mTORC1 activity while increasing Akt
activity (Figure 6D). Protein synthesis, ribosomal biogenesis, and
lipid metabolism, which are mediated by mTORC1 (Porstmann
et al., 2009), are major consumers of cellular energy metabolism,
whereas Akt is a major positive regulator of cellular energy
metabolism. Therefore, it is possible that the inhibition of
mTORC1 and the subsequent activation of Akt by FoxO were
evolved, first, to maintain the homeostatic balance between
Akt and mTOR complexes’ activities and, second, to maintain
cellular energy homeostasis under stress conditions. In sup-
port of this notion, we found that under conditions in which
FoxO3a/ cells display higher activity of mTORC1 and lower
activity of mTORC2 as compared to WT cells, they also have
a significantly reduced ATP:ADP ratio compared to WT cells
(Figure 6E).
Under certain stress conditions, when FoxO is activated it
could rescue cells from energy crisis prior to its full manifestation
and the full activation of AMPK. By elevating Sesn3, FoxO
reduces energy consumption, whereas by elevating Akt activity
it increases energy production. These effects of FoxO are likely
transient and occur in a temporal manner because once Akt is
activated, it inhibits FoxO and activates mTORC1, thus returning
the cells to a normal status (Figure 6D) unless FoxO is activated
regardless of Akt status. This could occur under stress condi-
tions that activate FoxO, overcoming FoxO’s inhibition by Akt
phosphorylation (Figure 6D). For example, it was shown that
the phosphorylation of FoxO by Jun-N-terminal kinase (JNK)
(Essers et al., 2004) or by the mammalian Ste20-like kinaselopmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Inc. 599
Figure 6. FoxO’s Deficiency Affects mTORC1 and mTORC2 Activities
(A) The knockdown of FoxO1 in FoxO3a/ MEFs, under standard culture conditions, increases mTORC1 activity and decreases mTORC2 activity. FoxO3a/
MEFs were transiently transfected with FoxO1 or control RNAi. A total of 48 hr after transfection, total protein lysates were subjected to immunobloting. mTORC1
and mTORC2 activities were deduced from the levels of Ser371 phosphorylation on S6K1 and Ser473 phosphorylation on Akt, respectively.
(B) mTORC1 activity is higher, whereas Akt activity is lower, in FoxOa3/ cells than in control wild-type cells when cultured at low glucose levels.
(C) Knocking down FoxO1 in Tsc2/ cells decreases Rictor expression and the Rictor-mTOR complex, decreasing Akt activity and increasing mTORC1 activity.
TSC2/ MEFs were transiently transfected with FoxO1 or control RNAi. A total of 48 hr after transfection, total proteins were harvested and subjected to
coimmunoprecipitation with mTOR antibody and immunoblotting with specific antibodies.
(D) A schematic illustration depicting the interplay between Akt, FoxO, and mTOR. In the excess of growth factors and nutrients, Akt inactivates FoxO and
activates mTORC1. mTORC1 then induces a negative-feedback loop to inhibit Akt. The inhibition of Akt by mTORC1 would activate FoxO to elevate Sesn3
and Rictor, which, in turn, inhibit mTORC1 and subsequently activate Akt, thereby maintaining a homeostatic balance between Akt and mTOR activities. Under
conditions of limited growth factors and nutrients or under other stress conditions, the ability of Akt to inhibit FoxO is impaired or FoxO is activated regardless of
Akt, thereby further elevating Sesn3 and Rictor to suppress mTORC1 activity and reduce energy consumption, while maintaining Akt activity to increase energy
production.
(E) The intracellular ATP:ADP ratio in FoxO3a-proficient and FoxO3a-deficeint cells.
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translocation to the nucleus.
To test this hypothesis experimentally, we used an isogenic
pair of WT and FoxO3a/MEFs. We first examined the relative
activities of mTORC1 and Akt in these cells under reduced
serum concentrations, and 5 mM instead of 25 mM glucose.
As shown in Figure 7A, at all serum concentrations that were
tested, the relative activity of Akt was higher than the relative
activity of mTORC1 in WT cells. In contrast, in FoxO3a/ cells,
the relative activity of mTORC1 was higher than the relative
activity of Akt at all serum concentrations. Importantly, at the
lowest serum concentration (1% FBS), mTORC1 activity was
markedly reduced relative to Akt activity in WT cells, whereas
in FoxO3a/ cells mTORC1 activity remains relatively higher600 Developmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Iand and to a similar extent as at higher serum concentrations.
The relative mTORC1/Akt activity in the two cell lines at the
different serum concentrations is correlated with levels of
Sesn3 expression (Figure S6A). These results support the idea
that FoxO serves as a rheostat that coordinates energy
consumption (mTORC1 activity) and energy production (Akt
activity), particularly when growth factors are limited. To further
verify this possibility, we followed the kinetics of mTORC1 and
Akt activities immediately after exposure to 1% FBS. Clearly,
Akt and mTORC1 activities are reduced with a similar kinetics
in WT cells, but not in FoxO3a/ cells (Figure 7B).
To determine if the same phenomenon occurs upon exposure
to oxidative stress that activates FoxO regardless of the phos-
phorylation of FoxO by Akt (Brunet et al., 2004), we examinednc.
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H2O2. Because the induction of FoxO’s nuclear translocation
by H2O2 occurs very rapidly, this experiment was performed at
26C to enable kinetics analyses. Under these conditions, the
onset of FoxO’s entry to the nucleus occurs15 min after expo-
sure to H2O2 (see insert Figure 7C, upper panel). Subsequently,
FoxO transiently elevated the expression of Sesn3 and, to a
lesser extent, Rictor (Figures S6B and S6C). As expected, Akt
activity was elevated immediately after exposure to H2O2 due
to the inactivation of PTEN (Leslie et al., 2003) (Figure 7C).
However, at these time points, in WT cells, mTORC1 activity
was reduced relative to Akt activity. At later time points, in WT
cells, Akt and mTORC1 activities were coordinated (Figure 7C).
In contrast, mTORC1 activity in FoxO3a/ cells had remained
relatively higher than Akt activity at all time points and did not
significantly decrease even when Akt activity was markedly
reduced (Figure 7C).
Collectively, these results support the model depicted in
Figure 6D, and they provide strong evidence that FoxO is
required to coordinate mTORC1 and Akt activities, particularly
under stress conditions.
DISCUSSION
We have demonstrated that FoxO regulates mTORC1 and Akt
activities in mammalian cells. Activation of FoxO inhibits
mTORC1, but upregulates Akt, activity, whereas FoxO defi-
ciency elevates mTORC1, but diminishes Akt, activity. Mecha-
nistically, we unraveled new regulatory circuits underlying the
interplay between Akt, FoxO, and mTOR.
Our results identified two mechanisms by which FoxO
suppresses mTORC1 activity. The first mechanism is TSC2
dependent and is mediated by the elevation of Sesn3. Like
Sesn1 and Sesn2, Sesn3 elevates the activity of AMPK. The exact
mechanism by which Sestrins elevate AMPK activity and inhibit
Tsc2 activity is not known, but it was shown that Sesn2 interacts
with AMPK (Budanov and Karin, 2008). Interestingly, it was
recently shown that the scaffolding proteins, kinase suppressors
of Ras1 and 2 (KSR1 and KSR2), physically interact with AMPK
and activate it (Costanzo-Garvey et al., 2009). Although the exact
mechanism by which these interactions with AMPK result in its
activation is not known, they set the stage for a new paradigm
whereby interaction of AMPK with certain proteins that by them-
selves may not possess enzymatic activity could increase its
activity. While this paper was in a late stage of revision, it was
shown that in Drosophila, the activation of FoxO by oxidative
stress induces sestrin expression, which, in turn, inhibits
TORC1 (Lee et al., 2010), indicating that this mechanism is highly
conserved.
The second mechanism is TSC2 independent and is medi-
ated, at least in part, through the elevation of Rictor by FoxO.
The elevation of Rictor reduced mTORC1 activity, in part,
through the decrease in Raptor-mTOR association. However,
this may not fully explain the dramatic effect of FoxO1 activation
on the rapamycin-sensitive phosphorylation site of 4E-BP1. One
possibility to consider is that the increase in Rictor redistributes
mTOR within the cell. The redistributed mTOR may reassemble
with Raptor, but in a nonactive complex, as it may not have
access to Rheb (Sancak et al., 2008). We also showed twoDevemechanisms by which FoxO elevates Akt activity: first, the
suppression of mTORC1 by FoxO contributes to the activation
of Akt via the inhibition of the negative-regulatory loop; and,
second, the elevation of Rictor and the subsequent increase in
mTORC2 activity. Obviously, the contribution of each mecha-
nism to the inactivation of mTORC1 and to the activation of Akt
would be dependent on the cell’s milieu. It is likely that the ratio
of mTORC1 to mTORC2 in a given cell type could also determine
the extent by which these mechanisms contribute to mTORC1
and Akt activities.
We have considered other potential mechanisms by which
FoxO might elevate Akt activity and reduce mTORC1 activity. It
was reported that the pseudokinase tribble 3 (Trb3) inhibits Akt
activity (Du et al., 2003), and that FoxO1 may elevate Akt activity
by suppressing Trb3 expression (Matsumoto et al., 2006). FoxO1
suppressesed Trb3 mRNA expression (Figure S7A), but although
the onset of Akt activation occurs 4 hr post-FoxO activation
(Figure 4B), we observed downregulation of Trb3 mRNA only
8 hr after FoxO activation (Figure S7A). Importantly, the knock-
down of Trb3 did not have any significant effect on Akt phos-
phorylation either in the absence or the presence of activated
FoxO1 (Figure S7B).
It was reported that FoxO elevates the expression of Bnip3
(Mammucari et al., 2007), and it was independently reported
that Bnip3 inhibits mTORC1 activity downstream of TSC2 by
interfering with Rheb activity (Li et al., 2007). We therefore exam-
ined whether the elevation of Bnip3 by FoxO could contribute to
the attenuation of mTORC1 activity by FoxO in Tsc2-deficient
cells. However, although we confirmed that activated FoxO1
elevates the expression of Bnip3 mRNA, the onset of Bnip3
mRNA induction occured at 16 hr post-FoxO1 activation,
whereas mTORC1 activity is fully suppressed after 8 hr post-
FoxO1 activation (Figure S7C). Furthermore, the knockdown of
Bnip3 did not interfere with the effect of FoxO on mTORC1
activity.
Our results strongly support the idea that FoxO coordinates
mTORC1 and Akt activities to maintain a balance between a
major cellular energy consumer, mTORC1, and a major energy
producer, Akt. Under normal physiological conditions, FoxO
may act as a rheostat that mediates a homeostatic balance
between the activities of Akt and mTOR complexes (Figure 6D).
This could also explain why we have not observed a dramatic
inhibition of mTORC1 when we express activated FoxO. While
FoxO inhibits mTORC1, it is also activating Akt, which in turn
activates mTORC1; therefore, the net result is a significant
mTORC1 inhibition, but not a dramatic inhibition. Under stress
conditions FoxO, by modulating Akt and mTORC1 activities,
may act as a gatekeeper to prevent energy crisis. The role of
FoxO under stress conditions is manifested by the results in
Figure 7, showing that FoxO is required to maintain low mTORC1
activity, relative to Akt activity, under stress conditions, thus,
reducing energy consumption while maintaining energy produc-
tion under stress conditions.
The inhibition of mTORC1 activity by FoxO transcription
factors could also be evolved as a negative-feedback mecha-
nism that restrains hyperactivation of mTORC1. When mTORC1
is hyperactivated it elicits the inhibition of Akt, enabling the
activation of FoxO transcription factors, which in turn inhibit
hyperactivated mTORC1.lopmental Cell 18, 592–604, April 20, 2010 ª2010 Elsevier Inc. 601
Figure 7. FoxO Is Required to Maintain Homeostatic Balance between Akt and mTORC1 Activities under Stress Conditions
(A) FoxO regulates the relative activities mTORC1 and Akt in response to growth factor limitations. Immortalized isogenic wild-type or FoxO3a/ MEFs were
cultured in DMEM medium containing different percentages of serum for 24 hr. Whole-cell lysates and mRNA were extracted and subjected to immunoblotting.
A representative immunoblot is shown (upper panel). Relative mTORC1 activity (p-S6K/S6K) and Akt activity (p-Akt/Akt) was quantified from two independent
experiments (bottom panel). Data are presented as the mean ± standard error of the mean.
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phenocopy the cellular responses to the inhibition of mTORC1;
therefore, it is possible that FoxO exerts some of its reported
effects through the inhibition of mTORC1. For example, both
the activation of FoxO and the inhibition of mTORC1 elicit cell
cycle arrest or attenuation of cell proliferation. Likewise, both
the activation of FoxO and the inhibition of mTORC1 elicit cellular
atrophy (Ohanna et al., 2005; Sandri et al., 2004). The activation
of mTORC1 is known to inhibit autophagy, and it was also shown
that autophagy could be mediated by the activation of FoxO
(Mammucari et al., 2007). Our results suggest that this could
be explained, in part, by the ability of FoxO to inhibit mTORC1.
Finally, the activation of FoxO could extend organismal and
cellular life spans (Greer and Brunet, 2005), whereas the activa-
tion of mTORC1 could promote cellular senescence (Zhang
et al., 2003), and the inhibition of TORC1 extends life spans in
worms and flies (Kapahi and Zid, 2004). Based on our results,
it is possible that FoxO activation extends organismal and
cellular life spans, in part via the inhibition of mTORC1.
In summary, our results provided an additional mechanism
by which a delicate balance between Akt and mTORC1 activities
is maintained, and an additional mechanism by which Akt
regulates mTORC1 activity. Our results also have broader impli-
cations, suggesting that some of the cellular or the organismal
consequences of FoxO activation could be explained by its
ability to inhibit mTORC1.EXPERIMENTAL PROCEDURES
Details of reagents, antibodies, plasmids, retroviruses, lentiviruses, adenovi-
ruses, and quantitative real-time PCR are provided in Supplemental Experi-
mental Procedures.Cell Lines, Cell Culture, Transfection, and Protein Extraction
Mouse embryonic fibroblast (MEFs) include Tsc2+/p53/, Tsc2/p53/,
and dominant-negative p53-immortalized FoxO3a+/+ and FoxO3a/.
MCF7 (human breast adenocarcinoma), NIH 3T3 (mouse fibroblast cell line),
Rat1a (mAkt) (rat fibroblast cell line), and U2OS (human osteosarcoma) cell
lines were cultured in DMEM containing 10% FBS. The DOV13 (human ovarian
carcinoma) cell line was cultured in MEM containing 10% FBS. For experiments
comparing mTORC1 and Akt activities in wild-type and FoxO3a/ MEFs
(Figure 7), cells were cultured in final 5 mM glucose with the indicated
percentage of dialyzed serum. DNA or RNAi transfections were performed
with Lipofectamine 2000 (Invitrogen). For the transfection of RNAi, 80,000 cells
were seeded on a 3 cm dish 1 day before transfection. siRNAs (100 nM; Thermo
Scientific Dharmacon) were diluted and mixed with 5 ml Lipofectamine 2000 to
transfect one sample. For other transient transfections, 6–10 mg DNA of expres-
sion plasmids was used to transfect one 6 cm dish with 60% confluent cells.
For immunoblotting, protein extract was prepared as described previously
(Hahn-Windgassen et al., 2005).(B) Immortalized FoxO3a wild-type and knockout MEFs were cultured in 10% se
medium for the indicated time points. Total cell lysates were extracted and su
(upper panel). Relative mTORC1 activity (p-S6K/S6K) and Akt activity (p-Akt/Akt
presented as the mean ± standard error of the mean.
(C) FoxO regulates the relative activities mTORC1 and Akt in response to oxidat
with 0.5 mM H2O2 and were harvested at the indicated time points at 26
C, then s
of FoxO to the nucleus, in response to H2O2 at 26
C. Wild-type MEFs were tran
Subcellular localization of FoxO was observed by following the GFP signal with
after exposure to H2O2. The middle panel shows a representative immunoblot o
relative mTORC1 activity (p-S6K/S6K) and Akt activity (p-Akt/Akt) quantified from
error of the mean.
DeveImmunoprecipitation and In Vitro Kinase Assays
For coimmunoprecipitation, cells were incubated in 0.3% CHAPS mTOR lysis
buffer as described previously (Sarbassov et al., 2004). For each sample,
500 mg protein was used for incubation with mTOR antibody (Cell Signaling)
at a 1:50 dilution and rotation for 3 hr. A total of 30 ml 50% protein A/G agarose
was then added and incubated for an additional hour. Immunoprecipitates
were washed three times with mTOR lysis buffer and once with IP wash buffer
(50 mM HEPES [pH 7.5], 40 mM NaCl, 2 mM EDTA) and resuspended in
sample buffer for immunoblotting analysis. Kinase assays were performed in
15 ml at 30C for 20 min and contained washed mTOR or Rictor immunoprecip-
itates; myc-S6K1 (purified from HEK293 cells treated with rapamycin) or
100 ng recombinant 4E-BP protein, purified from E. coli; or inactive Akt
(Upstate 14-279), in kinase assay buffer (100 mM ATP, 25 mM HEPES
[pH 7.4], 50 mM KCl, 20% glycerol, 10 mM MgCl2, 4 mM MnCl2, 1 mM DTT,
and Roche phosphatase inhibitor cocktail) modified from previous publication
(Kim et al., 2002). Reactions were stopped by the addition of 5 ml 4x sample
buffer, and proteins were subjected to immunoblotting with phosphospecific
antibodies. To prepare S6K1 as a substrate for the kinase assay, HEK293 cells
were transiently transfected with myc-S6K1 vector for 48 hr. Transfected
HEK293 cells were serum starved for 24 hr and treated with 100 nM rapamycin
for 1 hr before harvesting. Cells were lysed by CHAPS lysis buffer and
subjected to myc antibody during a 1 hr incubation at 4C. Protein A/G agarose
beads were added to pull down myc-S6K1 and then incubated with mTOR
immunoprecipitates to bind mTOR complexes. Immunoprecipitates were
washed three times with mTOR lysis buffer, followed by the in vitro kinase
assay as described above. To prepare Akt1 as a substrate, the inactive Akt
purchased from Upstate was subjected to Lambda protein phosphatase
(NEB) for 1 hr at 30C. The phosphatase was heat inactivated for 30 min at
65C, and the reaction was subjected to pan-Akt antibody (Cell Signaling)
during a 1 hr incubation at 4C. Protein A/G agarose beads were added to
pull down Akt and then incubated with Rictor immunoprecipitates to bind
mTORC2 complexes. Immunoprecipitates were washed three times with
mTOR lysis buffer, followed by the in vitro kinase assay as described above.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Experimental Procedures and seven
figures and is available with this article online at doi:10.1016/j.devcel.2010.
03.008.
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